Literature DB >> 29487026

Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis.

Claudio Ricci1, Riccardo Casadei2, Giovanni Taffurelli2, Davide Campana2, Valentina Ambrosini3, Carlo Alberto Pacilio2, Donatella Santini3, Nicole Brighi3, Francesco Minni2.   

Abstract

BACKGROUND: Adjuvant therapy after curative surgery for sporadic pancreatic neuroendocrine tumor (pNETs) is not currently recommended, assuming that all patients could be cured by a radical resection. The aim of our study is to establish how many and which kind of patients remained uncured after radical resection of pNET.
METHODS: Retrospective study involving 143 resected sporadic pNETs. The survival analysis was carried out using the cure model, describing the cure fraction and the excess of risk recurrence. Multivariate analyses were made in order to evaluate the non negligible effect of demographics, clinical and pathological factors on survival parameters. The results were reported as percentages, fractions, ORs and HRs with 95% confidence interval (95 CI %).
RESULTS: The cure fraction and the excess of hazard rate of the whole population were 57.1% (37.4-74.6, 95% CI) and 0.06 (0.03-0.07, 95% CI), respectively. Two independent factors were related to the cure fraction: TNM stage (OR 0.27 ± 0.17; P = 0.002) and grading (OR 0.11 ± 0.18; P = 0.004). Considering the excess of hazard rate, only two independent factors were related to an increased risk of recurrence: TNM stage (HR 3.49 ± 1.12; P = 0.004) and grading (HR 4.93 ± 1.82; P < 0.001).
CONCLUSION: The radical surgery has a high probability of cure in stages I-II or in grading 1 while, in stages III-IV or in grading 3 tumors, surgery alone failed to achieve a "cure". A multimodal treatment should be employed in order to avoid a recurrence of the disease.
Copyright © 2018 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29487026     DOI: 10.1016/j.pan.2018.02.008

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.

Authors:  Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience.

Authors:  Claudio Ricci; Davide Campana; Chiara Casadei; Carlo Ingaldi; Valentina Ambrosini; Nico Pagano; Donatella Santini; Cristina Mosconi; Nicole Brighi; Laura Alberici; Francesco Minni; Riccardo Casadei
Journal:  Endocrine       Date:  2019-02-22       Impact factor: 3.633

4.  Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study.

Authors:  Charlotte M Heidsma; Diamantis I Tsilimigras; Flavio Rocha; Daniel E Abbott; Ryan Fields; George A Poultsides; Clifford S Cho; Alexandra G Lopez-Aguiar; Zaheer Kanji; Alexander V Fisher; Bradley A Krasnick; Kamran Idrees; Eleftherios Makris; Megan Beems; Casper H J van Eijck; Elisabeth J M Nieveen van Dijkum; Shishir K Maithel; Timothy M Pawlik
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.